Serina Therapeutics, Inc. (SER) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
601 GENOME WAY HUNTSVILLE, AL 35806 |
| State of Incorp. | AL |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 345 | 645 | 584 | 527 | 2,352 | 6,707 | |||
| Cash and cash equivalent | 345 | 645 | 584 | 527 | 2,352 | 6,707 | |||
| Restricted cash and investments | 695 | 634 | |||||||
| Receivables | 57 | 4 | 25 | 326 | 363 | 131 | |||
| Prepaid expense | |||||||||
| Other current assets | |||||||||
| Other undisclosed current assets | 352 | 1,109 | 991 | 1,430 | 1,339 | 1,015 | |||
| Total current assets: | 754 | 2,453 | 2,234 | 2,283 | 4,054 | 7,853 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | ✕ | ||||||||
| Operating lease, right-of-use asset | ✕ | ||||||||
| Property, plant and equipment | 1,126 | 90 | |||||||
| Long-term investments and receivables | 10,554 | ||||||||
| Accounts and financing receivable, after allowance for credit loss | 10,554 | ||||||||
| Intangible assets, net (including goodwill) | 607 | 738 | 870 | 1,592 | 2,151 | 2,709 | |||
| Intangible assets, net (excluding goodwill) | 607 | 738 | 870 | 1,592 | 2,151 | 2,709 | |||
| Deposits noncurrent assets | 50 | 50 | 111 | 19 | |||||
| Restricted cash and investments | 50 | 50 | |||||||
| Total noncurrent assets: | 11,211 | 788 | 920 | 1,642 | 3,388 | 2,818 | |||
| TOTAL ASSETS: | 11,965 | 3,241 | 3,154 | 3,925 | 7,442 | 10,671 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 2,176 | 1,034 | 771 | 1,656 | 1,582 | 1,416 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 212 | 228 | 263 | 254 | ||
| Accounts payable | 1,413 | 568 | 193 | 761 | 420 | 150 | |||
| Accrued liabilities | 529 | 273 | |||||||
| Other undisclosed accounts payable and accrued liabilities | 234 | 193 | 366 | 667 | 899 | 1,012 | |||
| Deferred revenue | 275 | 283 | ✕ | ||||||
| Debt | 3,672 | 7,646 | 436 | 428 | |||||
| Other liabilities | 625 | ||||||||
| Due to related parties | ✕ | ✕ | 141 | 7,140 | 1,960 | 64 | 82 | ||
| Contract with customer, liability | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 317 | ||
| Other undisclosed current liabilities | 66 | 1,257 | 1,056 | 1,030 | 940 | ||||
| Total current liabilities: | 5,914 | 10,078 | 8,967 | 5,357 | 3,297 | 2,440 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 693 | 10,478 | |||||||
| Long-term debt, excluding current maturities | 693 | 10,478 | |||||||
| Liabilities, other than long-term debt | 6,062 | 3,964 | 1,528 | ||||||
| Deferred revenue | 64 | ✕ | |||||||
| Due to related parties | ✕ | ✕ | 6,062 | 3,900 | 1,528 | ||||
| Operating lease, liability | ✕ | ||||||||
| Other undisclosed noncurrent liabilities | |||||||||
| Total noncurrent liabilities: | 693 | 10,478 | 6,062 | 3,964 | 1,528 | ||||
| Total liabilities: | 6,607 | 20,556 | 15,029 | 9,321 | 4,825 | 2,440 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 5,469 | (17,212) | (11,832) | (5,116) | 2,218 | 7,447 | |||
| Common stock | 4 | 4 | 4 | 4 | 4 | ||||
| Common stock held by subsidiary | (250) | (3,248) | |||||||
| Additional paid in capital | 136,482 | 98,994 | 93,912 | 91,810 | 88,353 | 81,499 | |||
| Accumulated other comprehensive income (loss) | 143 | 69 | (2) | ||||||
| Accumulated deficit | (131,013) | (116,210) | (105,748) | (97,073) | (86,208) | (74,054) | |||
| Other undisclosed equity, attributable to parent | 250 | 3,248 | |||||||
| Equity, attributable to noncontrolling interest | (111) | (103) | (43) | (280) | 399 | 784 | |||
| Total equity: | 5,358 | (17,315) | (11,875) | (5,396) | 2,617 | 8,231 | |||
| TOTAL LIABILITIES AND EQUITY: | 11,965 | 3,241 | 3,154 | 3,925 | 7,442 | 10,671 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 142 | 34 | 144 | 1,868 | 1,728 | 1,396 | ||
| Cost of revenue | (40) | (13) | (19) | (158) | (244) | (364) | ||
| Gross profit: | 102 | 21 | 125 | 1,710 | 1,484 | 1,032 | ||
| Operating expenses | (10,062) | (6,996) | (8,164) | |||||
| Other undisclosed operating income (loss) | 73 | 106 | (12,277) | |||||
| Operating income (loss): | (9,887) | (6,975) | (7,933) | 1,710 | 1,484 | (11,245) | ||
| Nonoperating income (expense) | (4,924) | (3,547) | (649) | |||||
| Other nonoperating income | 11 | 13 | 448 | |||||
| Interest and debt expense | (4,900) | (3,335) | 437 | (487) | (54) | |||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (12,349) | (13,666) | ||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (19,711) | (13,857) | (8,145) | (11,126) | (12,236) | (11,245) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 34,511 | 24,357 | (540) | |||||
| Income (loss) from continuing operations before income taxes: | 14,800 | 10,500 | (8,685) | (11,126) | (12,236) | (11,245) | ||
| Other undisclosed income (loss) from continuing operations | (21,022) | 8,688 | ||||||
| Income (loss) from continuing operations: | 14,800 | (10,522) | 3 | (11,126) | (12,236) | (11,245) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (100) | (11,126) | (12,236) | (11,245) | |
| Loss from discontinued operations | (103) | |||||||
| Other undisclosed net loss | (29,611) | (8,585) | ||||||
| Net loss: | (14,811) | (10,522) | (8,685) | (11,126) | (12,236) | (11,245) | ||
| Net income attributable to noncontrolling interest | 8 | 60 | 111 | 230 | 229 | |||
| Other undisclosed net income (loss) attributable to parent | 10 | 150 | (148) | 3,514 | ||||
| Net loss attributable to parent: | (14,803) | (10,462) | (8,675) | (10,865) | (12,154) | (7,502) | ||
| Undistributed earnings (loss) allocated to participating securities, basic | ||||||||
| Other undisclosed net income available to common stockholders, basic | 17,254 | |||||||
| Net income (loss) available to common stockholders, diluted: | (14,803) | (10,462) | 8,579 | (10,865) | (12,154) | (7,502) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (14,811) | (10,522) | (8,685) | (11,126) | (12,236) | (11,245) | ||
| Other comprehensive loss | (10,462) | (8,818) | (10,791) | (12,083) | (7,572) | |||
| Comprehensive loss: | (14,811) | (20,984) | (17,503) | (21,917) | (24,319) | (18,817) | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 8 | 60 | 111 | 230 | (229) | |||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 10,402 | 8,675 | 10,904 | 11,776 | 26,847 | |||
| Comprehensive income (loss), net of tax, attributable to parent: | (14,803) | (10,522) | (8,828) | (10,902) | (12,313) | 7,801 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.